Key Highlights

  • Ardelyx (NASDAQ:ARDX) reported third-quarter 2026 total Revenue of USD 127.7 million on November 3, 2026, up from USD 110.3 million a year earlier, with product revenue of USD 125.5 million, up 19%.
  • IBSRELA revenue reached USD 96.3 million, up 23% year over year, while XPHOZAH contributed USD 29.2 million, up 7%, according to the company release for the quarter ended September 30, 2026.
  • The quarter produced Operating Income of USD 4.0 million but a net loss of USD 0.7 million, after USD 15.1 million of share-based compensation, with USD 285.3 million of cash and short-term investments.
  • Published market data showed shares near USD 3.14, up 3.47%, on Volume of about 2.8 million shares; the snapshot date is not confirmed, and the move is modest.

Third-Quarter Revenue Climbs to USD 127.7 Million

Ardelyx (NASDAQ:ARDX) released third-quarter 2026 results on November 3, 2026, reporting total revenue of USD 127.7 million against USD 110.3 million in the same quarter of 2025. Total product revenue was USD 125.5 million, a gain of 19%. The company develops and sells medicines for gastrointestinal and kidney-related conditions, led by IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for lowering phosphorus in dialysis patients. Operating income was USD 4.0 million, compared with USD 4.7 million a year earlier, so profit from operations slipped even as sales grew. The net loss was USD 0.7 million, or USD 0.00 per share, against a USD 1.0 million net loss in the third quarter of 2025.

IBSRELA Growth, XPHOZAH Lag and Reiterated Guidance

IBSRELA generated USD 96.3 million, up 23%, and now supplies most of the revenue, while XPHOZAH generated USD 29.2 million, up 7%. The company reiterated full-year 2026 IBSRELA revenue guidance of USD 350 million to USD 370 million and XPHOZAH guidance of USD 110 million to USD 120 million. Operating expenses are expected to stay below USD 500 million for the year. Ardelyx (NASDAQ:ARDX) also said enrollment in its Phase 3 ACCEL trial in chronic idiopathic constipation finished ahead of schedule, with topline data expected in the second half of 2027. A new US Patent covering the commercial formulations of both products is scheduled to issue on November 10, 2026, per the release.

Penny Stock Risks: Thin Trading and Reversible Moves

At about USD 3.14 on the screened quote, Ardelyx (NASDAQ:ARDX) sits below the USD 5 level that defines a penny stock, even though it has a commercial product line. Any Penny Stock can swing on a small number of trades, spreads can be wide, and a quoted gain of 3.47% can reverse quickly, so the move should not be read as a trend. Cash of USD 285.3 million supports operations, yet the net loss shows profitability is not yet established. Share-based compensation of USD 15.1 million in the quarter adds dilution to weigh. Volume near 2.8 million shares is a published market data point whose date could not be verified.

Where Things Stand

Ardelyx (NASDAQ:ARDX) trades near USD 3.14 mainly because the penny stock is pairing 19% product revenue growth with a still-thin bottom line, not because of a confirmed rally. The November 3, 2026 release showed revenue of USD 127.7 million, IBSRELA up 23% and guidance reiterated, which supports the Business story. Against that, the quarter ended in a small net loss, XPHOZAH grew only 7%, and the screened gain of 3.47% is too small and too undated to signal momentum. The next markers are the patent issuance scheduled for November 10, 2026, progress toward the full-year guidance ranges and the ACCEL data in the second half of 2027.